[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.83.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 11, 2005

Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(18):2211-2212. doi:10.1001/jama.293.18.2212-a

To the Editor: The Clinical Review by Dr Sink and colleagues1 erroneously presents the results of one of the cited studies.2 On page 602, the article states “ . . . the intention-to-treat analysis found only the 16-mg/d dose to be significantly better than placebo . . . with no benefit for the other doses,” using the Neuropsychiatric Inventory as the outcome. In fact, both the 16-mg/d and the 24-mg/d galantamine doses were found to be significantly better than placebo for the Neuropsychiatric Inventory as well as for all other outcome measures.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×